The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | The introduction of non-covalent BTKis to the treatment paradigm for R/R CLL
Lydia Scarfò, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Scientific Institute, Milan, Italy, comments on the introduction of non-covalent BTK inhibitors (BTKis) to the treatment paradigm for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). She mentions the recent approval of pirtobrutinib based on positive trial results and the potential future use of this agent in earlier treatment lines. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Recently the EMA approved the pirtobrutinib and it’s use is approved in relapsed/refractory CLL after exposure to a continuous BTK inhibitor. So now we have these novel agents that based on the results in a heavily pre-treated population in the Phase I/II study and in the Phase III trial is able to achieve deep responses. And we are now um trying to collect longer follow-up in order to understand the durability of these responses and based on the EMA approval we might have the chance to use this drug even at earlier line of treatments and this would lead to a, I suppose, better response and long-term disease control as we see from the results of Phase III trials where patients who weren’t exposed to venetoclax for example achieved a much longer time to next treatment compared to those who were previously exposed to venetoclax regimens...
Recently the EMA approved the pirtobrutinib and it’s use is approved in relapsed/refractory CLL after exposure to a continuous BTK inhibitor. So now we have these novel agents that based on the results in a heavily pre-treated population in the Phase I/II study and in the Phase III trial is able to achieve deep responses. And we are now um trying to collect longer follow-up in order to understand the durability of these responses and based on the EMA approval we might have the chance to use this drug even at earlier line of treatments and this would lead to a, I suppose, better response and long-term disease control as we see from the results of Phase III trials where patients who weren’t exposed to venetoclax for example achieved a much longer time to next treatment compared to those who were previously exposed to venetoclax regimens.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
